Evidence map›Paper›PMID 35326464›Full record

ReviewCells2022

Mesenchymal Stromal Cells in Ischemic Brain Injury.

Beverly Brooks, Dominique Ebedes, Ahsan Usmani, Joaquin Vega Gonzales-Portillo, Daniel Gonzales-Portillo, Cesario V Borlongan

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
4.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Beverly BrooksCenter of Excellence for Aging and Brain Repair, University of South Florida Morsani College of Medicine, 12901 Bruce B Downs Blvd, Tampa, FL 33612, USA.
Dominique EbedesCenter of Excellence for Aging and Brain Repair, University of South Florida Morsani College of Medicine, 12901 Bruce B Downs Blvd, Tampa, FL 33612, USA.
Ahsan UsmaniCenter of Excellence for Aging and Brain Repair, University of South Florida Morsani College of Medicine, 12901 Bruce B Downs Blvd, Tampa, FL 33612, USA.
Joaquin Vega Gonzales-PortilloUniversidad Peruana de Ciencias Aplicadas, Prolongación Primavera 2390, Lima 15023, Peru.
Daniel Gonzales-PortilloDepartment of Psychology, University of Florida, 945 Center Dr, Gainesville, FL 32611, USA.
Cesario V BorlonganCenter of Excellence for Aging and Brain Repair, University of South Florida Morsani College of Medicine, 12901 Bruce B Downs Blvd, Tampa, FL 33612, USA.ORCID 0000-0002-2966-9782
University of South Florida · USPeruvian University of Applied Sciences · PEUniversity of Florida · US

Funding

MR Analysis of Pre-Conditioned Human Mesenchymal Stem Cells for Stroke TherapyR01NS102395 · NINDS · FLORIDA STATE UNIVERSITY · PI GRANT, SAMUEL COLLES · 2017 to 2021
$1.7M
Re-Establishing Vascular Integrity in ALS via Endothelial Cell TransplantR01NS090962 · NINDS · UNIVERSITY OF SOUTH FLORIDA · PI BORLONGAN, CESARIO V, GARBUZOVA-DAVIS, SVITLANA NICOLAI · 2015 to 2019
$1.6M
Optimizing Approaches to Endovascular Therapy of Acute Ischemic StrokeR21NS109575 · NINDS · UNIVERSITY OF SOUTH FLORIDA · PI MOKIN, MAXIM · 2019 to 2019
$420k
NINDS NIH HHS R01 NS090962NINDS NIH HHS R01 NS102395NINDS NIH HHS R21 NS109575
6 · The paper itself

Abstract

Ischemic brain injury represents a major cause of death worldwide with limited treatment options with a narrow therapeutic window. Accordingly, novel treatments that extend the treatment from the early neuroprotective stage to the late regenerative phase may accommodate a much larger number of stroke patients. To this end, stem cell-based regenerative therapies may address this unmet clinical need. Several stem cell therapies have been tested as potentially exhibiting the capacity to regenerate the stroke brain. Based on the long track record and safety profile of transplantable stem cells for hematologic diseases, bone marrow-derived mesenchymal stromal cells or mesenchymal stromal cells have been widely tested in stroke animal models and have reached clinical trials. However, despite the translational promise of MSCs, probing cell function remains to be fully elucidated. Recognizing the multi-pronged cell death and survival processes that accompany stroke, here we review the literature on MSC definition, characterization, and mechanism of action in an effort to gain a better understanding towards optimizing its applications and functional outcomes in stroke.

Indexed as

Brain InjuriesMesenchymal Stem CellsMesenchymal Stem Cell TransplantationStrokeAnimalsBrainHumansbrain injurymesenchymal stem cellsmesenchymal stromal cellsstem cellsstroke

Identifiers

PMID35326464
PMCPMC8947674
OpenAlexW4221015360

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.